inner-banner-bg

International Journal of Cancer Research & Therapy(IJCRT)

ISSN: 2476-2377 | DOI: 10.33140/IJCRT

Impact Factor: 1.3

Bortezomib Induced Blepharitis: a Case Report

Abstract

Ahmad Khalil, Pamela Sfeir, Antoine Abi Abboud, Kamal AlZahran, Elise Slim and Evelyne Helou

Introduction: Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma, and has known manageable toxicities. Blepharitis is an inflammatory condition of the eyelid that leads to formation of chalazia both causing visual field disturbance. Bortezomib induced blepharitis has not been well reported in the literature.

Case: we present a case of 76 year old lady with multiple myeloma who developed bortezomib-induced blepharitis and chalazia. Patient was successfully treated after topical ocular therapy, systemic antibiotherapy and omission of bortezomib.

PDF